Table 1 Associations of PGM5 expression with clinicopathological factors in CRC patients
From: PGM5 is a promising biomarker and may predict the prognosis of colorectal cancer patients
Variable | Number | PGM5 level | P value | |
|---|---|---|---|---|
Low | High | |||
Age (years) | 0.574 | |||
< 65 | 27 | 17 (21.5%) | 10 (12.7%) | |
≥ 65 | 52 | 36 (45.6%) | 16 (20.3%) | |
Gender | 0.314 | |||
Male | 39 | 25 (31.6%) | 14 (17.7%) | |
Female | 40 | 28 (35.4%) | 12 (15.2%) | |
Tumor size (cm) | 0.083 | |||
< 5 | 27 | 19 (24.1%) | 8 (10.1%) | |
≥ 5 | 52 | 34 (43.0%) | 18 (22.8%) | |
Lymph node metastasis | 0.041 | |||
N0 | 48 | 28 (35.4%) | 20 (25.3%) | |
N1 | 22 | 16 (20.3%) | 6 (7.6%) | |
N2 | 9 | 9 (11.4%) | 0 (24.1%) | |
Clinical stage | 0.039 | |||
I–II | 48 | 20 (25.3%) | 28 (35.4%) | |
III–IV | 31 | 6 (7.6%) | 25 (31.6%) | |
Survival | 0.005 | |||
Live | 40 | 21 (26.6%) | 19 (24.1%) | |
Dead | 39 | 32 (40.5%) | 7 (8.9%) | |